Debevoise & Plimpton LLP is advising Johnson & Johnson on a global co-development and commercialization agreement between Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. Total consideration for the transaction is approximately $1 billion.

Theravance Biopharma together with Janssen will jointly develop and commercialize TD-1473 in inflammatory intestinal diseases. TD-1473 is a novel, potent, orally administered and intestinally restricted pan-Janus kinase (JAK) inhibitor in clinical development, with the potential to treat a range of inflammatory intestinal diseases.

The Debevoise team is led by partners Henry Lebowitz and Kevin Rinker and includes partner Sue Meng and associates Michelle M. Hillenbrand and Andrew G. Jamieson.

Debevoise & Plimpton LLP is a premier law firm with market-leading practices, a global perspective and strong New York roots. We deliver effective solutions to our clients’ most important legal challenges, applying clear commercial judgment and a distinctively collaborative approach.